Web Page-Disease

Disease Phase Study No. Summary Status Total
Hide details for Advanced CancersAdvanced Cancers
Hide details for Phase IPhase I
2014-1056   Phase 1a/1b Study of the Oral TRK Inhibitor LOXO-101 in Subjects with Adult Solid Tumors  Open  
2014-1006   A Phase I Study of IDH305 in Patients with Advanced Malignancies that Harbor IDH1R132 Mutations  Open  
2014-0891   A Phase 1 study of KBP-5209 in patients with advanced solid tumors  Open  
2014-0878   A Multicenter Phase 1 Ascending Dose Study of DCC-2701 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Solid Tumors  Open  
2014-0763   Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors  Open  
2014-0605   A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination with Standard Chemotherapy in Patients with Advanced and/or Treatment-Refractory Solid Tumors  Open  
2014-0495   A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients with Advanced Solid Tumors  Open  
2014-0384   A Phase 1 Dose-Escalation Study of LY2940680 in Patients with Advanced Cancer  Open  
2014-0338   A Phase 1 Study of LY3164530, a Bispecific Antibody Targeting MET and EGFR, in Patients with Advanced or Metastatic Cancer   Open  
2014-0328   Pharmacokinetics of Oral Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function  Open  
2014-0193   A Phase 1b Trial of LY2606368 in Combination with
Cisplatin or Cetuximab in Advanced and/or Metastatic
2014-0137   An open-label Phase I dose-escalation study to evaluate
the safety, tolerability, maximum tolerated dose,
pharmacokinetics, and pharmacodynamics of the anti-
C4.4a antibody drug conjugate BAY 1129980 in
subjects with advanced solid tumors known to express
2013-0866   A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects with Advanced Malignancies  Open  
2013-0833   A Phase I Trial of Regorafenib and Cetuximab in Patients with Advanced Malignancy  Open  
2013-0823   A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1  Open  
2013-0813   A Phase Ib Open-Label, Multi-Center, Dose Escalation and Expansion Study of Orally Administered MEK162 plus BYL719 in Adult Patients with Selected Advanced Solid Tumors   Open  
2013-0765   Phase I Study of Fourth Ventricle Infusions of Autologous ex vivo-expanded NK Cells in children with recurrent/refractory malignant posterior fossa tumors of the central nervous system.
NOAH’s (New Opportunity, Advancing Hope) Protocol
2013-0699   First-In-Human, Dose-Escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate (HuMax-TF-ADC) in Patients with Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor  Open  
2013-0684   A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection  Open  
2013-0665   Phase I Study of MLN0128 (NSC# 768435) in Combination with Ziv-Aflibercept (NSC# 724770) in Patients with Advanced Cancers  Open  
2013-0616   A Phase 1 Study of LY3009120 in Patients with Advanced or Metastatic Cancer  Open  
2013-0574   Phase 1 Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignances  Open  
2013-0549   Phase I Safety Study of Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-Refractory Solid Tumor Malignancies  Open  
2013-0525   A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects with Advanced Malignancies  Open  
2013-0511   A Phase I Study of MLN9708 and Vorinostat to Target Autophagy in Patients with Advanced p53 Mutant Malignancies   Open  
2013-0466   A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in
Patients With Advanced Solid Tumors or Lymphoma
2013-0257   A Phase 1 Multiple Ascending Dose Study of DS-3032b, an oral MDM2 inhibitor, in subjects with advanced solid tumors or lymphomas  Open